A week ago, Inspire Medical Systems, Inc. (NYSE:INSP) came out with a strong set of quarterly numbers that could potentially lead to a re-rate of the stock. The company beat forecasts, with revenue of US$203m, some 2.8% above estimates, and statutory earnings per share (EPS) coming in at US$0.60, 894% ahead of expectations. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.

View our latest analysis for Inspire Medical Systems

After the latest results, the 17 analysts covering Inspire Medical Systems are now predicting revenues of US$950.1m in 2025. If met, this would reflect a sizeable 26% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to surge 73% to US$1.91. Yet prior to the latest earnings, the analysts had been anticipated revenues of US$949.1m and earnings per share (EPS) of US$1.34 in 2025. There was no real change to the revenue estimates, but the analysts do seem more bullish on earnings, given the sizeable expansion in earnings per share expectations following these results.

There's been no major changes to the consensus price target of US$238, suggesting that the improved earnings per share outlook is not enough to have a long-term positive impact on the stock's valuation. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. There are some variant perceptions on Inspire Medical Systems, with the most bullish analyst valuing it at US$270 and the most bearish at US$197 per share. This shows there is still a bit of diversity in estimates, but analysts don't appear to be totally split on the stock as though it might be a success or failure situation.

Of course, another way to look at these forecasts is to place them into context against the industry itself. We would highlight that Inspire Medical Systems' revenue growth is expected to slow, with the forecast 20% annualised growth rate until the end of 2025 being well below the historical 44% p.a. growth over the last five years. Juxtapose this against the other companies in the industry with analyst coverage, which are forecast to grow their revenues (in aggregate) 8.2% per year. So it's pretty clear that, while Inspire Medical Systems' revenue growth is expected to slow, it's still expected to grow faster than the industry itself.